GlassScriptPhysician profile
Patricia K Roddey
NPI 1255352647
$4,207.01
in general payments reported to CMS, 2019-2025
28 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $98.72 · 2021: $32.35 · 2022: $548 · 2023: $758 · 2024: $1,051 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,823 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,822.63 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $666.20 | 2019-2025 | Tremfya |
| Abbvie INC. | $628.71 | 2022-2025 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $382.90 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $370.25 | 2022-2025 | Ilumya |
| Pfizer INC. | $280.23 | 2019-2025 | |
| Hill Dermaceuticals, INC. | $276.35 | 2025 | Tolak |
| Dermavant Sciences, INC. | $236.20 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $225.39 | 2019 | |
| Amgen INC. | $214.83 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $151.82 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $128.52 | 2022-2025 | Taltz, Ebglyss |
| Dermira, INC. | $119.28 | 2019 | |
| Incyte Corporation | $72.29 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $69.02 | 2025 | Nemluvio |
| Leo Pharma INC. | $55.73 | 2023-2025 | Adbry, Anzupgo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.22 | 2022-2023 | |
| Botanix Sb INC | $40.63 | 2025 | Sofdra |
| Organon LLC | $36.48 | 2025 | Vtama |
| Almirall LLC | $30.54 | 2023 | Klisyri |
| Arcutis Biotherapeutics, INC. | $29.07 | 2023 | |
| Genzyme Corporation | $24.87 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.29 | 2025 | Spevigo |
| Xeris Pharmaceuticals, INC. | $23.22 | 2022 | |
| Harmony Biosciences LLC | $19.22 | 2022 | |
| Insulet Corporation | $18.22 | 2022 | |
| Journey Medical Corporation | $14.36 | 2025 | |
| Vivus LLC | $12.94 | 2019 | |
| Shire North American Group INC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Roddey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.